Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Dunbar AJ, Gondek LP, O’Keefe CL, Makishima H, Rataul MS, Szpurka H et al. 250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. Cancer Res 2008; 68: 10340–10357.

    Article  Google Scholar 

  2. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi K, Zoi C, McGuire C et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009; 113: 6182–6192.

    Article  CAS  PubMed  Google Scholar 

  3. Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J et al. Mutations of E3 ligase Cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol 2009; 27: 6109–6116.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Sanada M, Suzuki T, Shih LY, Otsu M, Kato M, Yamasaki S et al. Gain-of-function of mutated CBL tumour suppressor in myeloid neoplasms. Nature 2009; 460: 904–908.

    Article  CAS  PubMed  Google Scholar 

  5. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951.

    Article  CAS  PubMed  Google Scholar 

  6. Gelsi-Boyer V, Cervera N, Bertucci F, Trouplin V, Rémy V, Olschwang S et al. Genes expression profiling separates chronic myelomonocytic leukaemia in two molecular subtypes. Leukemia 2007; 21: 2359–2362.

    Article  CAS  PubMed  Google Scholar 

  7. Gelsi-Boyer V, Trouplin V, Adélaïde J, Aceto N, Remy V, Pinson S et al. Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer 2008; 8: 299–314.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Ohtake F, Baba A, Takada I, Okada M, Iwasaki K, Miki H et al. Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature 2007; 444: 562–566.

    Article  Google Scholar 

  9. Take H, Watanabe S, Takeda K, Yu ZX, Iwata N, Kajigaya S . Cloning and characterization of a novel adaptor protein, CIN85, that interacts with c-Cbl. Biochem Biophys Res Commun 2000; 268: 321–328.

    Article  CAS  PubMed  Google Scholar 

  10. Soubeyran P, Kowanetz K, Szymkiewicz I, Langdon WY, Dikic I . Cbl-CIN85-endophilin complex mediates ligand-induced downregulation of EGF receptors. Nature 2002; 416: 183–187.

    Article  CAS  PubMed  Google Scholar 

  11. Bezsonova I, Bruce MC, Wiesner S, Lin H, Rotin D, Forman-Cay JD . Interactions between the three CIN85 SH3 domains and ubiquitin: implications for CIN85 ubiquitination. Biochemistry 2008; 47: 8937–8949.

    Article  CAS  PubMed  Google Scholar 

  12. Havrylov S, Rzheptskyy Y, Malinowska A, Drobot L, Redowicz MJ . Proteins recruited by the SH3 domains of Ruk/CIN85 adaptor identified by LC-MS/MS. Protein Sci 2009; 7: 21.

    Article  Google Scholar 

  13. Aissouni Y, Zapart G, Iovanna JL, Dikic I, Soubeyran P . CIN85 regulates the ability of MEKK4 to activate the p38 MAP kinase pathway. Biochem Biophys Res Comm 2005; 338: 808–814.

    Article  CAS  PubMed  Google Scholar 

  14. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41: 838–842.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by Institut Paoli-Calmettes, Inserm, and grants from the Association pour la Recherche contre le Cancer (no. 4992).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M Chaffanet.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adélaïde, J., Gelsi-Boyer, V., Rocquain, J. et al. Gain of CBL-interacting protein, a possible alternative to CBL mutations in myeloid malignancies. Leukemia 24, 1539–1541 (2010). https://doi.org/10.1038/leu.2010.135

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2010.135

This article is cited by

Search

Quick links